Precision Medicine in Oncology
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Attend An Event
State of the Science Summit
Regional Seminar Series
Giants of Cancer Care
Precision Medicine in Oncology
<< View More Conferences
2019 Genitourinary Cancers Symposium
Oncology Conference Multimedia
View more videos >>
Dr. Siefker-Radtke on Bempegaldesleukin Plus Nivolumab in Urothelial Carcinoma
Dr. Powles on Potential With Durvalumab in Papillary RCC
Dr. Desai on MRI Imaging for Bone Metastases in CRPC
Oncology Conference Articles
Bempegaldesleukin/Nivolumab Combo May Address Unmet Need in Metastatic Urothelial Carcinoma
Arlene O. Siefker-Radtke, MD, discusses the promising preliminary data with bempegaldesleukin plus nivolumab in patients with metastatic urothelial carcinoma and the next steps for this combination.
Pembrolizumab Shows Promising Activity in Non-Clear Cell RCC
Single-agent pembrolizumab (Keytruda) showed encouraging antitumor activity as first-line treatment in patients with non-clear cell renal cell carcinoma, especially in those with papillary or unclassified histology.
PARP Inhibitors Hold Promise in mCRPC and Biallelic DNA Repair Gene Defects
Evan Y. Yu, MD, highlights 2 key studies with PARP inhibitors in metastatic castration-resistant prostate cancer and discussed challenges that need to be addressed in this space in order to further progress.
Modest Activity With Durvalumab/Savolitinib Combo in Papillary RCC Not Enough to Warrant Further Studies
The overall response rate achieved with with the combination of savolitinib and durvalumabin in patients with metastatic papillary renal cell carcinoma in the phase II CALYPSO study did not meet the prespecified criterion for further investigation of the regimen.
Pembrolizumab/Cabozantinib Combo Is Well Tolerated, Shows Activity in Metastatic RCC
The combination of pembrolizumab (Keytruda) and cabozantinib (Cabometyx) has antitumor activity in patients with previously treated metastatic renal cell carcinoma and is tolerated at their separate approved doses for this indication.
Sacituzumab Govitecan Active in Advanced Urothelial Carcinoma
Sacituzumab govitecan exhibited significant clinical activity in an open-label, single-arm phase I/II basket study of patients with heavily pretreated, relapsed/refractory metastatic urothelial cancer.
Layered Treatment With Radium-223 and Abiraterone May Reduce Skeletal Events in mCRPC
In a real-world setting, patients with metastatic castration-resistant prostate cancer who received radium-223 dichloride with abiraterone acetate in a layered fashion experienced a lower rate of symptomatic skeletal events compared with those who received the treatments concurrently.
Enzalutamide Extends Radiographic PFS in Metastatic Hormone-Sensitive Prostate Cancer
The addition of enzalutamide (Xtandi) to androgen deprivation therapy significantly prolonged radiographic progression-free survival compared with ADT alone in men with metastatic hormone-sensitive prostate cancer.
Darolutamide Improves Metastasis-Free Survival in Nonmetastatic CRPC
Darolutamide added to androgen deprivation therapy significantly improved metastasis-free survival compared with placebo plus ADT in patients with nonmetastatic castration-resistant prostate cancer enrolled in the phase III ARAMIS trial.
Nivolumab/Ipilimumab OS Benefit Sustained in Long-Term Follow-Up for Frontline RCC
Nivolumab combined with low-dose ipilimumab continued to demonstrate strong responses and a survival benefit at 30 months’ follow-up as a frontline treatment for patients with intermediate- and poor-risk advanced renal cell carcinoma.
Pembrolizumab/Axitinib Combo Improves Survival in Frontline RCC
The combination of pembrolizumab (Keytruda) and axitinib (Inlyta) was associated with a significantly longer progression-free and overall survival compared with sunitinib (Sutent) in treatment-naïve patients with clear cell metastatic renal cell carcinoma.
Hormonal Agents Induce Improved OS in African Americans With Chemo-Naive mCRPC
African-American men with metastatic castration-resistant prostate cancer treated with novel hormonal therapies—namely abiraterone acetate or enzalutamide—lived 20% longer than their Caucasian counterparts.
LuPSMA May Improve Survival in Heavily Pretreated mCRPC
The novel targeted radiation therapy lutetium-177 PSMA-617 showed strong clinical activity and the potential to improve survival in heavily pretreated men with PSMA-positive metastatic castration-resistant prostate cancer.
FDA Approvals in MCL and Beta Thalessemia-Associated Anemia, Priority Review in HCC, and More
FDA Approves Acalabrutinib for CLL
PROfound Data Could Lead to First PARP Inhibitor Approval in mCRPC
ASCO Guidelines on VTE Add New Oral Agents
Dr. Mato on Ibrutinib-Based Combinations in CLL
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2019
Intellisphere, LLC. All Rights Reserved.